Regulation - Research, Roche


Current filters:


Popular Filters

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling

UK MPs express concerns on clinical trial data transparency and Tamiflu stockpiling


The UK House of Commons Public Accounts Committee is calling for all data on drugs being prescribed in…

Anti-viralsNorthern EuropePharmaceuticalRegulationResearchRocheTamifluUK

Briefs: Elan tender offer; German drug price review; Daiichi Sankyo pays milestone


Ireland-based drugmaker Elan (NYSE: ELN) yesterday reported final results of its modified Dutch auction…

ActemraAmgenAnticalinBayerElanFinancialNovo NordiskPharmaceuticalPradaxaPricingProliaRegulationResearchRocheVictozaXarelto

Genentech Ph III study of omalizumab shows promise in CIU


Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

Safety of Novartis' Lucentis in VI-DME confirmed with new data; efficacy in CNV


New data revealed yesterday by Swiss drug major Novartis (NOVN: VX) showed that Lucentis (ranibizumab)…


Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients


Swiss drug major Roche (ROG: SIX) US subsidiary Genentech has announced updated results from the Phase…

BiotechnologyGenentechOncologyPharmaceuticalRegulationResearchRocheT-DM1trastuzumab emtansine

Roche to file for trastuzumab emtansine this year, on positive Ph III results


Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…


Back to top